Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis
중증 악화 COVID-19 폐렴에 대한 토실리주맙: 성향 점수 분석
Article
[키워드] Admission
Analysis
anti-IL-6 receptor
baseline
C-reactive protein
compassionate use
Concomitant medication
control group
COVID-19
CRP
cytokine
Cytokine storm
discharged
disease severity
fibrinogen
groups
hospital
humanized
IL-6
IMPROVE
inclusion criteria
Inflammation
inflammatory parameters
intensive care
intensive care unit
Interaction
interleukin-6
intravenous tocilizumab
male
mechanical ventilation
methodology
neutropenia
outcome
oxygen
oxygen flow
Oxygen therapy
Patient
patients treated
Pneumonia
Probability
prospective cohort
Rate
rates of infection
reduced
reduction
score
selected
serum
significantly lower
statistical significance
survival
Symptom
therapy
Tocilizumab
Treatment
treatment with tocilizumab
Trial
underlying conditions
variables
ventilatory support
were assessed
Withdrawal
worsening
[DOI] 10.1007/s10875-020-00911-6 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s10875-020-00911-6 PMC 바로가기 [Article Type] Article